Swiss Semiconductors Stock News

Roche Holding (SWX:ROG) reported promising Phase II results for petrelintide, its investigational obesity drug. The trial showed clinically meaningful, sustained weight loss with a favorable tolerability profile. The company is advancing discussions and further development of petrelintide in chronic weight management. For investors following SWX:ROG, this update puts a fresh spotlight on Roche's efforts in obesity treatments, an area attracting intense attention across healthcare. The...

Naturenergie holding AG recently reported its 2025 results, with EBIT of €214 million, higher annual profit, and gross investments of €174 million focused on system-relevant infrastructure, renewable generation, and customer-focused energy solutions, while also declaring an annual dividend of CHF 0.9000 per share payable on May 4, 2026. The company signalled that 2026 EBIT could fall to around €120 million due to weaker marketing prices and regulatory pressures, yet it still plans to lift...

SFS Group (SWX:SFSN) has just posted its FY 2025 numbers, reporting first half revenue of CHF 1.6b and basic EPS of CHF 2.86. This provides an early indication of how the rest of the year might shape investor expectations. The company has reported revenue of CHF 1.56b in the first half of 2024, CHF 1.50b in the second half of 2024, and CHF 1.55b in the first half of 2025. Over the same periods, basic EPS was CHF 3.00, then CHF 3.21, and then CHF 2.86, giving a clear view of how the top line...

mobilezone holding ag (SWX:MOZN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 429.6 million and EPS of CHF 0.41 setting the tone for the year. The company has seen revenue move from CHF 476.1 million and EPS of CHF 0.44 in the first half of 2024 to CHF 525.3 million and EPS of CHF 0.0757 in the second half, before landing at the current run rate that feeds into trailing 12 month revenue of CHF 958.3 million and EPS of CHF 0.3618. With trailing net margins...

SIG Group AG has released its full-year 2025 results, reporting sales of €3,248.7 million versus €3,328.5 million a year earlier and moving from net income of €194.5 million to a net loss of €87 million. The swing from earnings per share of €0.51 to a basic and diluted loss per share of €0.23 highlights a sharp deterioration in profitability that may prompt investors to reassess the company’s earnings outlook. We’ll now examine how this move from profit to net loss in 2025 could reshape SIG...

Cicor Technologies (SWX:CICN) has reported H1 2025 revenue of CHF 280.7 million and basic EPS of CHF 1.93, setting the stage after a year in which earnings grew 49.7% and net profit margin moved from 3.8% to 4.5%. Over the past three reported halves, revenue has moved from CHF 231.3 million in H1 2024 to CHF 249.5 million in H2 2024 and now CHF 280.7 million in H1 2025, while basic EPS shifted from CHF 2.69 to CHF 3.52 and then CHF 1.93, with margins now doing more of the heavy lifting in the...

Comet Holding (SWX:COTN) has reported its FY 2025 first half results with revenue of CHF 227.2 million and EPS of CHF 1.01, while the trailing twelve months show revenue of CHF 483.2 million and EPS of CHF 5.02 based on the data provided. The company has seen revenue move from CHF 189.3 million and EPS of CHF 0.52 in the first half of 2024 to CHF 256.0 million and EPS of CHF 4.02 in the second half of 2024, setting up FY 2025 against a backdrop of improving net margins and profitability that...

ALSO Holding (SWX:ALSN) has announced a new €120 million share buyback program, targeting up to 9.74% of its share capital for treasury use, acquisitions, liquidity, and management incentives. See our latest analysis for ALSO Holding. The buyback news comes after a weak patch for the shares, with a 30 day share price return showing a decline of 16.53% and a year to date share price return showing a decline of 23.16%. The 1 year total shareholder return shows a decline of 37.67%, which...

If you are wondering whether Swisscom is still reasonably priced after its recent run, you are not alone. This article will help you frame that question clearly. Swisscom's share price closed at CHF 718.0, with returns of 8.5% over 30 days, 24.0% year to date and 44.1% over 1 year. The 7 day return of a 0.5% decline shows that the ride has not been entirely one way. Recent coverage around Swisscom has focused on its role as a major Swiss telecom operator, including ongoing attention on its...

Bossard Holding (SWX:BOSN) FY 2025 Results Set the Tone for Margins and Growth Expectations Bossard Holding (SWX:BOSN) opened FY 2025 with first half revenue of CHF547.9 million and net income of CHF37.4 million, setting a clear earnings benchmark for investors watching how profits track through the rest of the year. The company reported revenue of CHF509.4 million and net income of CHF41.3 million in the first half of 2024, followed by CHF477.0 million and CHF31.1 million in the second half...

Latest FY 2025 headline numbers V-ZUG Holding (SWX:VZUG) has opened FY 2025 with first half revenue of CHF 271.2 million and basic EPS of CHF 0.25, setting a cautious tone around profitability and growth. The company has seen revenue move from CHF 284.1 million in 1H 2024 to CHF 307.6 million in 2H 2024, with EPS shifting from CHF 1.36 to CHF 1.97 over the same periods, before settling at CHF 0.25 in the latest half. This leaves investors focused squarely on how margins are holding up through...

Idorsia reports recent commercial traction for its insomnia drug Quvivic, including broader public reimbursement across major European and North American markets. The company highlights plans for further international rollout of Quvivic and updates on late stage pipeline assets, including pediatric studies. Partnered programs are progressing clinically, with collaborations moving forward alongside Idorsia’s own R&D efforts. Idorsia (SWX:IDIA) is drawing attention as it updates investors on...

European Medicines Agency’s CHMP issues a positive opinion on remibrutinib for adults with chronic spontaneous urticaria who do not respond adequately to standard therapies. CHMP recommendation is based on clinical trial data and represents a key regulatory step for SWX:NOVN in allergic and immunological conditions. Novartis announces plans for a new radioligand therapy manufacturing site in Texas to support production of cancer therapies in the US. Novartis, traded as SWX:NOVN, is a large...

If you are wondering whether Sandoz Group is still attractively priced after its recent run, this article will help you size up what you are really paying for each Swiss franc of the business. The shares closed at CHF64.66, with a 7.0% return over the last month, a 13.0% return year to date, and a 71.1% return over the past year, although the last 7 days saw an 8.1% decline that may have changed how some investors view the risk and reward trade off. Recent news flow around Sandoz Group has...

Galderma Group (SWX:GALD) reports full year sales above $5b, marking a milestone for its dermatology focused portfolio. The company highlights new product launches it describes as having blockbuster potential across its prescription and aesthetics segments. Fresh clinical data show Nemluvio delivering long term efficacy and safety in prurigo nodularis, an area of high unmet medical need. Regulatory approval of new device technology supports further expansion of Galderma's aesthetics...

Adecco Group (SWX:ADEN) shares are in focus after the company reported fourth quarter and full year 2025 results, along with upcoming Board changes that include planned departures and a defined end date for the current Chair. See our latest analysis for Adecco Group. The earnings and Board updates come after a weaker share price patch, with a 1-day share price return of 2.03% at CHF21.06, compared with a year-to-date share price return of 10.23% and a 1-year total shareholder return of...

Roche Holding (SWX:ROG) reported positive Phase II ZUPREME-1 results for petrelintide in chronic weight management, highlighting efficacy and safety data. Genentech, part of Roche Group, announced significant findings from the pivotal Phase III FENhance 1 study, with fenebrutinib showing meaningful effects in relapsing multiple sclerosis. Roche Holding, trading at around CHF351.5, is drawing attention as these two clinical updates arrive alongside a 20.0% return over the past year and a...

UBS Group has proposed changes to its Board of Directors, nominating Agustín Carstens and Luca Maestri. Several long serving directors are set to step down as the bank refreshes its governance structure. The board changes come while UBS continues integrating Credit Suisse and responding to evolving regulatory expectations. For investors watching SWX:UBSG, these board moves come with the shares at CHF30.59 and after a mixed run, with a 7.0% return over the past year alongside a 19.9% decline...

How VAT Group’s FY 2025 Numbers Set Up the Next Chapter VAT Group (SWX:VACN) has wrapped up FY 2025 with second half revenue of CHF 515.6 million and basic EPS of CHF 3.63, alongside trailing twelve month revenue of CHF 1.07 billion and EPS of CHF 7.15 framing the latest print. Over recent periods, the company has seen half yearly revenue move from CHF 492.6 million in 2H 2024 to CHF 515.6 million in 2H 2025, while half yearly EPS shifted from CHF 3.92 to CHF 3.63, and trailing twelve month...

What the latest earnings tell you about Zug Estates Holding Zug Estates Holding (SWX:ZUGN) just released full year 2025 figures, with sales of CHF 87.72 million, revenue of CHF 91.5 million, and net income of CHF 85.18 million drawing fresh investor attention. These headline numbers give you a fresh reference point for thinking about the stock, its current valuation, and how the business is converting its real estate and hotel activities into bottom line results. See our latest analysis for...

HIAG Immobilien Holding FY 2025 earnings snapshot HIAG Immobilien Holding (SWX:HIAG) has just posted its FY 2025 numbers, with first half revenue of CHF 47.6 million and basic EPS of CHF 4.42, while funds from operations came in at CHF 1.90 per share, giving investors a fresh read on both cash generation and headline profitability. Over recent periods the company has seen revenue move from CHF 70.3 million in the first half of 2024 to CHF 65.8 million in the second half of 2024 and then to...

What Holcim’s 2025 earnings mean for shareholders Holcim (SWX:HOLN) has moved into focus after reporting full year 2025 results, with sales of CHF 15,724 million compared to CHF 16,201 million a year earlier, and a sharp jump in reported net income and earnings per share. See our latest analysis for Holcim. Despite the strong headline earnings, Holcim’s 1 month share price return of an 18.15% decline and a 14% share price pullback year to date suggest momentum has cooled, even as the 1 year...

Implenia (SWX:IMPN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 1.9b and basic EPS of CHF 1.80 setting the tone for how the year is shaping up. The company has seen revenue move from CHF 1.7b in the first half of 2024 to CHF 1.9b in the latest half, while basic EPS shifted from CHF 1.43 to CHF 1.80 over the same periods, creating a results season in which investors are weighing growth prospects against how efficiently those sales are turning into profit. See...

What Swisscom’s Recent Share Performance Tells You Swisscom (SWX:SCMN) has seen its share price move in recent weeks, with a 0.8% decline over the past day contrasting with gains over the past week, month and past 3 months. For context, the stock shows a 0.9% return over the past week, 12.3% over the past month and 28.2% over the past 3 months, with a 45.7% total return over the past year. See our latest analysis for Swisscom. The recent pullback in Swisscom’s share price to CHF714.5 comes...